Form 4: Jazz Pharmaceuticals Director Kenneth O'Keefe Reports Stock Transactions
SEC Form 4 Filing
Director Kenneth O'Keefe reports acquisition and disposal of Jazz Pharmaceuticals shares, including those to cover tax obligations.
Summary
- Kenneth O'Keefe, a director of Jazz Pharmaceuticals, reported transactions involving the company's ordinary shares.
- On August 2, 2024, O'Keefe acquired 3,731 shares at $0.00, related to restricted stock units vesting on July 25, 2025.
- On August 6, 2024, O'Keefe disposed of 1,484 shares at $111.35 to cover tax obligations.
- Following these transactions, O'Keefe directly owns 26,970 shares and indirectly owns 4,445 shares through a trust.
Sentiment
Score: 5
Explanation: The document reports routine stock transactions by a company director, which is neutral in sentiment.
Industry Context
Executive stock transactions are a normal part of corporate governance and are publicly disclosed to ensure transparency.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding director's stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/12/1997 | Date of The Kenneth W. O'Keefe Trust U/A/D |
| 07/25/2025 | Vesting date for restricted stock units |
| 08/02/2024 | Date of acquisition of shares |
| 08/06/2024 | Date of disposal of shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.